Rakesh K. Chandra

Rakesh K. Chandra

Auto-generated profile, based on publicly available information

Rakesh K. Chandra

Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University School of Medicine, Nashville, TN

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2016 in International Forum of Allergy & Rhinology
Verified
Journal Article
Open access
PDF file
RORichard R. Orlandi
Richard R. Orlandi
TKTodd T. Kingdom
Todd T. Kingdom
PHPeter H. Hwang
Peter H. Hwang
TSTimothy L. Smith
Timothy L. Smith
JAJeremiah A. Alt
Jeremiah A. Alt
DKDavid W. Kennedy
David W. Kennedy
Contributing Authors: Isam Alobid, MD, PhD1, Nithin D. Adappa, MD2, Henry P. Barham, MD3, Thiago Bezerra, MD4, Nadieska Caballero, MD5, Eugene G. Chang, MD6, Gaurav Chawdhary, MD7, Philip Chen, MD8, John P. Dahl, MD, PhD9, Anthony Del Signore, MD10, Carrie Flanagan, MD11, Daniel N. Frank, PhD12, Kai Fruth, MD, PhD13, Anne Getz, MD14, Samuel Greig, MD15, Elisa A. Illing, MD16, David W. Jang, MD17, Yong Gi Jung, MD18, Sammy Khalili, MD, MSc19, Cristobal Langdon, MD20, Kent Lam, MD21, Stella Lee, MD22, Seth Lieberman, MD23, Patricia Loftus, MD24, Luis Macias‐Valle, MD25, R. Peter Manes, MD26, Jill Mazza, MD27, Leandra Mfuna, MD28, David Morrissey, MD29, Sue Jean Mun, MD30, Jonathan B. Overdevest, MD, PhD31, Jayant M. Pinto, MD32, Jain Ravi, MD33, Douglas Reh, MD34, Peta L. Sacks, MD35, Michael H. Saste, MD36, John Schneider, MD, MA37, Ahmad R. Sedaghat, MD, PhD38, Zachary M. Soler, MD39, Neville Teo, MD40, Kota Wada, MD41, Kevin Welch, MD42, Troy D. Woodard, MD43, Alan Workman44, Yi Chen Zhao, MD45, David Zopf, MD46Contributing Author Affiliations: 1Universidad de Barcelona; 2University of Pennsylvania; 3Louisiana State University Health Sciences Center; 4Universidade de São Paulo; 5ENT Specialists of Illinois; 6University of Arizona; 7University of Oxford; 8University of Texas; 9University of Indiana; 10Mount Sinai Beth Israel; 11Emory University; 12University of Colorado; 13Wiesbaden, Germany; 14University of Colorado; 15University of Alberta; 16University of Alabama at Birmingham; 17Duke University; 18Sungkyunkwan University; 19University of Pennsylvania; 20Universidad de Barcelona; 21Northwestern University; 22University of Pittsburgh; 23New York University; 24Emory University; 25University of British Columbia; 26Yale University School of Medicine; 27Private Practice; 28Department of Otolaryngology, Hôtel‐Dieu Hospital, Centre de Recherche du Centre Hospitalier de l'Université de Montréal; 29University of Adelaide; 30Pusan National University; 31University of California, San Francisco; 32University of Chicago; 33University of Auckland; 34Johns Hopkins University; 35University of New South Wales, Australia; 36Stanford University; 37Washington University; 38Harvard Medical School; 39Medical University of South Carolina; 40Singapore General Hospital; 41Taho University; 42Northwestern University; 43Cleveland Clinic Foundation; 44University of Pennsylvania; 45University of Adelaide; 46University of Michigan

15 September 2015 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
WSWhitney W. Stevens
Whitney W. Stevens
COChristopher J. Ocampo
Christopher J. Ocampo
SBSergejs Berdnikovs
Sergejs Berdnikovs
MSMasafumi Sakashita
Masafumi Sakashita
MMMahboobeh Mahdavinia
Mahboobeh Mahdavinia
RSRobert P. Schleimer
Robert P. Schleimer
Rationale: The mechanisms that underlie the pathogenesis of chronic rhinosinusitis without nasal polyps (CRSsNP), chronic rhinosinusitis with nasal polyps (CRSwNP), and aspirin-exacerbated respiratory disease (AERD) are not clear. Objectives: To first evaluate the inflammatory profiles of CRSsNP and CRSwNP tissues and then to investigate whether clinical differences observed between CRSwNP and AERD are in part secondary to differences in inflammatory mediator expression within nasal polyp (NP) tissues. Methods: Expression levels of numerous inflammatory mediators were determined by quantitative real-time polymerase chain reaction, ELISA, and multiplex immunoassay. Measurements and Main Results: CRSwNP NP had increased levels of type 2 mediators, including IL-5 (P < 0.001), IL-13 (P < 0.001), eotaxin-2 (P < 0.001), and monocyte chemoattractant protein (MCP)-4 (P < 0.01), compared with sinonasal tissue from subjects with CRSsNP and control subjects. Expression of IFN-γ messenger RNA or protein was low and not different among the chronic rhinosinusitis subtypes examined. Compared with CRSwNP, AERD NP had elevated protein levels of eosinophil cationic protein (ECP) (P < 0.001), granulocyte–macrophage colony–stimulating factor (GM-CSF) (P < 0.01), and MCP-1 (P = 0.01), as well as decreased gene expression of tissue plasminogen activator (tPA) (P = 0.02). Despite the higher eosinophilia in AERD, there was no associated increase in type 2 mediator protein levels observed. Conclusions: CRSwNP was characterized by a predominant type 2 inflammatory environment, whereas CRSsNP did not reflect a classic type 1 milieu, as has been suggested previously. AERD can be distinguished from CRSwNP by elevated ECP levels, but this enhanced eosinophilia is not associated with elevations in traditional type 2 inflammatory mediators associated with eosinophil proliferation and recruitment. However, other factors, including GM-CSF, MCP-1, and tPA, may be important contributors to AERD pathogenesis.

1 September 2013 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
DNDeepti R. Nagarkar
Deepti R. Nagarkar
JPJulie A. Poposki
Julie A. Poposki
BTBruce K. Tan
Bruce K. Tan
MCMichael R. Comeau
Michael R. Comeau
APAnju T. Peters
Anju T. Peters
AKAtsushi Kato
Atsushi Kato

1 December 2015 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
KPKelly Pekala
Kelly Pekala
RCRakesh K. Chandra
Rakesh K. Chandra
JTJustin H. Turner
Justin H. Turner

1 May 2013 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
BTBruce K. Tan
Bruce K. Tan
RCRakesh K. Chandra
Rakesh K. Chandra
JPJonathan Pollak
Jonathan Pollak
AKAtsushi Kato
Atsushi Kato
DCDavid B. Conley
David B. Conley
BSBrian S. Schwartz
Brian S. Schwartz

27 July 2022 in BMJ
Verified
Journal Article
Open access
PDF file
BTBenjamin Kye Jyn Tan
Benjamin Kye Jyn Tan
RHRuobing Han
Ruobing Han
JZJoseph J Zhao
Joseph J Zhao
NTNicole Kye Wen Tan
Nicole Kye Wen Tan
EQEmrick Sen Hui Quah
Emrick Sen Hui Quah
STSong Tar Toh
Song Tar Toh
Objective: To clarify in patients with covid-19 the recovery rate of smell and taste, proportion with persistent dysfunction of smell and taste, and prognostic factors associated with recovery of smell and taste. Design: Systematic review and meta-analysis. Data sources: PubMed, Embase, Scopus, Cochrane Library, and medRxiv from inception to 3 October 2021. Review methods: Two blinded reviewers selected observational studies of adults (≥18 years) with covid-19 related dysfunction of smell or taste. Descriptive prognosis studies with time-to-event curves and prognostic association studies of any prognostic factor were included. Data extraction and synthesis: Two reviewers extracted data, evaluated study bias using QUIPS, and appraised evidence quality using GRADE, following PRISMA and MOOSE reporting guidelines. Using iterative numerical algorithms, time-to-event individual patient data (IPD) were reconstructed and pooled to retrieve distribution-free summary survival curves, with recovery rates reported at 30 day intervals for participants who remained alive. To estimate the proportion with persistent smell and taste dysfunction, cure fractions from Weibull non-mixture cure models of plateaued survival curves were logit transformed and pooled in a two stage meta-analysis. Conventional aggregate data meta-analysis was performed to explore unadjusted associations of prognostic factors with recovery. Main outcome measures: The primary outcomes were the proportions of patients remaining with smell or taste dysfunction. Secondary outcomes were the odds ratios of prognostic variables associated with recovery of smell and taste. Results: 18 studies (3699 patients) from 4180 records were included in reconstructed IPD meta-analyses. Risk of bias was low to moderate; conclusions remained unaltered after exclusion of four high risk studies. Evidence quality was moderate to high. Based on parametric cure modelling, persistent self-reported smell and taste dysfunction could develop in an estimated 5.6% (95% confidence interval 2.7% to 11.0%, I 2 =70%, τ 2 =0.756, 95% prediction interval 0.7% to 33.5%) and 4.4% (1.2% to 14.6%, I 2 =67%, τ 2 =0.684, 95% prediction interval 0.0% to 49.0%) of patients, respectively. Sensitivity analyses suggest these could be underestimates. At 30, 60, 90, and 180 days, respectively, 74.1% (95% confidence interval 64.0% to 81.3%), 85.8% (77.6% to 90.9%), 90.0% (83.3% to 94.0%), and 95.7% (89.5% to 98.3%) of patients recovered their sense of smell (I 2 =0.0-77.2%, τ 2 =0.006-0.050) and 78.8% (70.5% to 84.7%), 87.7% (82.0% to 91.6%), 90.3% (83.5% to 94.3%), and 98.0% (92.2% to 95.5%) recovered their sense of taste (range of I 2 =0.0-72.1%, τ 2 =0.000-0.015). Women were less likely to recover their sense of smell (odds ratio 0.52, 95% confidence interval 0.37 to 0.72, seven studies, I 2 =20%, τ 2 =0.0224) and taste (0.31, 0.13 to 0.72, seven studies, I 2 =78%, τ 2 =0.5121) than men, and patients with greater initial severity of dysfunction (0.48, 0.31 to 0.73, five studies, I 2 =10%, τ 2 <0.001) or nasal congestion (0.42, 0.18 to 0.97, three studies, I 2 =0%, τ 2 <0.001) were less likely to recover their sense of smell. Conclusions: A substantial proportion of patients with covid-19 might develop long lasting change in their sense of smell or taste. This could contribute to the growing burden of long covid. Systematic review registration: PROSPERO CRD42021283922.